{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:35:22Z","timestamp":1793406922740,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1038\/s41433-020-0778-3","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T12:03:53Z","timestamp":1580299433000},"page":"2076-2081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Vismodegib for periocular basal cell carcinoma: an international multicentre case series"],"prefix":"10.1038","volume":"34","author":[{"given":"H.","family":"Oliphant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Laybourne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Haridas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Edmunds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Althaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cranstoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. N.","family":"Rajak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"key":"778_CR1","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","volume":"366","author":"A Sekulic","year":"2012","unstructured":"Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl J Med. 2012;366:2171\u20139.","journal-title":"N. Engl J Med"},{"key":"778_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3286-5","volume":"17","author":"A Sekulic","year":"2017","unstructured":"Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long-term safety and efficacy of vismode- gib in patients with advanced basal cell carcinoma: final up- date of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17:332. https:\/\/doi.org\/10.1186\/s12885-017-3286-5.","journal-title":"BMC Cancer."},{"key":"778_CR3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","volume":"86","author":"N Basset-Seguin","year":"2017","unstructured":"Basset-Seguin N, Hauschild A, Kuntsfield R, Grob J, Dreno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Our J Cancer. 2017;86:334\u201348. https:\/\/doi.org\/10.1016\/j.ejca.2017.08.022.","journal-title":"Our J Cancer"},{"key":"778_CR4","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jamaophthalmol.2013.5018","volume":"131","author":"HS Gill","year":"2013","unstructured":"Gill HS, Moscato EE, Chang AL, Soon S, Silkiss RZ. Vismodegib for periocular and orbital basal cell carcinoma. JAMA Ophthalmol. 2013;131:1591\u20134.","journal-title":"JAMA Ophthalmol"},{"key":"778_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1136\/bjophthalmol-2018-312277","volume":"103","author":"O Sagiv","year":"2019","unstructured":"Sagiv O, Nagarajan P, Ferrarotto R, Kandi TJ, Thakar SD, Glisson BS, et al. Ocular Preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. Br J Ophthamol. 2019;103:775\u201380.","journal-title":"Br J Ophthamol"},{"key":"778_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ajo.2019.04.013","volume":"207","author":"M Eiger-Moscovich","year":"2019","unstructured":"Eiger-Moscovich M, Reich E, Tauber G, Berliner O, Priel A, Ben Simon G, et al. Efficacy of vismodegib for the treatment of orbital and advanced periocular basal cell carcinoma. Am J Ophthalmol. 2019;207:62\u201370. https:\/\/doi.org\/10.1016\/j.ajo.2019.04.013.","journal-title":"Am J Ophthalmol"},{"key":"778_CR7","doi-asserted-by":"publisher","first-page":"e1424","DOI":"10.1097\/GOX.0000000000001424","volume":"5","author":"KY Wong","year":"2017","unstructured":"Wong KY, Fife K, Lear JT, Price RD, Durrani AJ. Vismodegib for locally advanced periocular and orbital basal cell carci- noma: a review of 15 consecutive cases. Plast Reconstr Sur Glob Open. 2017;5:e1424.","journal-title":"Plast Reconstr Sur Glob Open"},{"key":"778_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2147\/IMCRJ.S168666","volume":"11","author":"DT Hogarty","year":"2018","unstructured":"Hogarty DT, Dewhurts NG, Burt B. Vismodegib and orbital excision for treating locally advanced basal cell carcinoma. Int Med Case Rep J. 2018;11:177\u20139. https:\/\/doi.org\/10.2147\/IMCRJ.S168666.","journal-title":"Int Med Case Rep J."},{"key":"778_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/DSS.0000000000001640.","volume":"45","author":"J Mathis","year":"2019","unstructured":"Mathis J, Doerr T, Lin E, Ibrahim SF. Oral hedgehog pathway inhibition as a means for ocular salvage in locally advanced intraorbital basal cell carcinoma. Dermatol Surg. 2019;45:17\u201325. https:\/\/doi.org\/10.1097\/DSS.0000000000001640.","journal-title":"Dermatol Surg."},{"key":"778_CR10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ajo.2015.04.040","volume":"160","author":"OK Ozgur","year":"2015","unstructured":"Ozgur OK, Yin V, Chou E, Ball S, Kies M, William WN, et al. Hedgehog pathway inhibi- tion for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome. Am J Ophthalmol. 2015;160:220\u20137.e2.","journal-title":"Am J Ophthalmol"},{"key":"778_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.ophtha.2004.11.036","volume":"112","author":"I Leibovitch","year":"2005","unstructured":"Leibovitch I, Mcnab A, Sullivan T, Davids G, Selva D. Orbital invasion by periocular basal cell carcinoma. Ophthalmology. 2005;112:717\u201323.","journal-title":"Ophthalmology."},{"key":"778_CR12","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1136\/bjo.2004.062471","volume":"89","author":"I Rahman","year":"2005","unstructured":"Rahman I, Cook AE, Leatherbarrow B. Orbital exenteration: a 13 year Manchester experience. Br J Ophthalmol. 2005;89:1335\u201340.","journal-title":"Br J Ophthalmol"},{"key":"778_CR13","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.ophtha.2010.02.013","volume":"117","author":"SN Madge","year":"2010","unstructured":"Madge SN, Khine AA, Thaller VT, Davis G, Malhotra R, McNab A, et al. Globe-sparing surgery for medial canthal Basal cell carcinoma with anterior orbital invasion. Ophthalmology. 2010;117:2222\u20138. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.013.","journal-title":"Ophthalmology."},{"key":"778_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.molonc.2014.09.003","volume":"9","author":"S Pricl","year":"2015","unstructured":"Pricl S, Cortelazzi B, Dal Col V, Marson D, Laurini E, Fermeglia M, et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015;9:389\u201397.","journal-title":"Mol Oncol"},{"key":"778_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jaad.2014.08.001","volume":"71","author":"T Brinkhuizen","year":"2014","unstructured":"Brinkhuizen T, Reinders MG, vanGeel M, Hendriksen AJ, Paulussen AD, Winnepenninckx VJ, et al. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. J Am Acad Dermatol. 2014;71:1005\u20138.","journal-title":"J Am Acad Dermatol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41433-020-0778-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-020-0778-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-020-0778-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:10:29Z","timestamp":1684617029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-0778-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,29]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1038\/s41433-020-0778-3","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,29]]},"assertion":[{"value":"30 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}